<DOC>
	<DOCNO>NCT00602433</DOCNO>
	<brief_summary>Studying sample blood laboratory patient receive erlotinib may help doctor learn effect erlotinib hormone level . This clinical trial look hormone change woman stage IIIB stage IV non-small cell lung cancer receive erlotinib .</brief_summary>
	<brief_title>Hormone Changes Women With Stage IIIB Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib</brief_title>
	<detailed_description>Patients undergo dermatology evaluation complete Polycystic Ovarian Syndrome ( PCOS ) research study questionnaire . Blood sample collect overnight fast . Samples analyze circulating level total bioavailable testosterone , dehydroepiandrosterone sulfate , sex hormone bind globulin . Serum luteinizing hormone , follicle stimulate hormone , fast glucose , insulin level also assess .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically confirm nonsmall cell lung cancer Stage IIIB ( effusion ) stage IV disease Must receive daily erlotinib hydrochloride 3 month Must hirsutism , acne , androgenic alopecia , amenorrhea , truncal weight gain , clinical phenotype associate syndrome androgen excess</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>advanced nonsmall cell lung cancer</keyword>
</DOC>